All In Biotech

Drug Trial Radar · NCT06096909

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population (EMPACT): A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,684 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,684

Planned (sponsor's estimate)

Start

Nov 11, 2023

Primary completion

Mar 1, 2028

Study completion Jun 1, 2028

Sponsor

Lead sponsor
China National Center for Cardiovascular DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Innovent Biologics, Inc.
First posted
Oct 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible. Compared with conventional lipid-lowering regimen, it is expected that the occurrence of major adverse cardiovascular events can still be reduced after drug discontinuation. Therefore, the optimization strategy of "for patients with ACS undergoing PCI, intensive lipid-lowering with PCSK9 monoclonal antibody can be started as soon as possible" is proposed.

Conditions

  • Acute Coronary Syndrome
  • Non ST Segment Elevation Acute Coronary Syndrome
  • Lipid Lowering, Vascular Inflammation

Interventions

  • TafolecimabDrug

    The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.

  • Cholesterol Absorption InhibitorDrug

    Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.

  • StatinDrug

    Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major adverse cardiovascular and cerebrovascular events (MACCE)Time frame: week 104

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Tangshan Central Hospital

    Tangshan, Hebei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.